Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Kim, Myoung-Jin Cha, Jinkwon Kim, Dong Lee, H. Lee, C. Nam, H. Nam, J. Heo (2011)
Increases in Cerebral Atherosclerosis According to CHADS2 Scores in Patients With Stroke With Nonvalvular Atrial FibrillationStroke, 42
P. Deedwania, Joel Lardizabal (2010)
Atrial fibrillation in heart failure: a comprehensive review.The American journal of medicine, 123 3
P. Camm, H. Bounameaux (2011)
EdoxabanDrugs, 71
Xarelto Ò (rivaroxaban): summary of product characteristics
Warfarin interactions with drugs, herbs and food
J. Eikelboom, M. O’Donnell, S. Yusuf, R. Diaz, G. Flaker, R. Hart, S. Hohnloser, C. Joyner, J. Lawrence, P. Pais, J. Pogue, D. Synhorst, S. Connolly (2010)
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.American heart journal, 159 3
J. Weitz, S. Connolly, Indravadan Patel, D. Salazar, S. Rohatagi, J. Mendell, H. Kastrissios, Jianqing Jin, S. Kunitada (2010)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThrombosis and Haemostasis, 104
A. Go, E. Hylek, Katherine Phillips, Yuchiao Chang, Lori Henault, Joeseph Selby, Daniel Singer (2001)
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.JAMA, 285 18
C. Ruff, R. Giugliano, E. Antman, S. Crugnale, Tomas Bocanegra, M. Mercuri, J. Hanyok, Indravadan Patel, M. Shi, D. Salazar, C. Mccabe, E. Braunwald (2010)
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).American heart journal, 160 4
F. Verheugt (2011)
[New antithrombotics for atrial fibrillation].Nederlands tijdschrift voor geneeskunde, 155
R. Lopes, J. Alexander, S. Al‐Khatib, J. Ansell, R. Díaz, J. Easton, B. Gersh, C. Granger, M. Hanna, J. Horowitz, E. Hylek, J. McMurray, F. Verheugt, L. Wallentin (2010)
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.American heart journal, 159 3
K. Lakshminarayan, C. Solid, A. Collins, David Anderson, C. Herzog (2006)
Atrial Fibrillation and Stroke in the General Medicare Population: A 10-Year Perspective (1992 to 2002)Stroke, 37
A.J. Camm (2010)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESCEur Heart J, 31
(2011)
Edoxaban TosylateAmerican Journal of Cardiovascular Drugs, 11
B. Beasley, E. Unger, R. Temple (2011)
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.The New England journal of medicine, 364 19
Hiroshi Yamanouchi, Masanori Tomonaga, H. Shimada, S. Matsushita, K. Kuramoto, Y. Toyokura (1989)
Nonvalvular atrial fibrillation as a cause of fatal massive cerebral infarction in the elderly.Stroke, 20 12
(2011)
Stroke prevention using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [online]. Available from URL: http://my
C. Walraven, R. Hart, G. Wells, P. Petersen, P. Koudstaal, A. Gulløv, B. Hellemons, Birgitte Koefed, A. Laupacis (2003)
A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin.Archives of internal medicine, 163 8
I. Ahrens, G. Lip, K. Peter (2010)
New oral anticoagulant drugs in cardiovascular diseaseThrombosis and Haemostasis, 104
S. Duggan, L. Scott, G. Plosker (2009)
Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.Drugs, 69 13
R.G. Hart, O. Benavente, R. McBride (1999)
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysisAnn Intern Med, 131
A. Holbrook, J. Pereira, R. Labiris, H. Mcdonald, J. Douketis, M. Crowther, P. Wells (2005)
Systematic overview of warfarin and its drug and food interactions.Archives of internal medicine, 165 10
S. Connolly, J. Eikelboom, C. Joyner, H. Diener, R. Hart, S. Golitsyn, G. Flaker, Á. Avezum, S. Hohnloser, R. Diaz, M. Talajic, Jun Zhu, P. Pais, A. Budaj, A. Parkhomenko, P. Janský, P. Commerford, R. Tan, K. Sim, B. Lewis, W. Mieghem, G. Lip, Jae Kim, Fernando Lanas-Zanetti, A. González-Hermosillo, A. Dans, M. Munawar, M. O’Donnell, J. Lawrence, G. Lewis, Rizwan Afzal, S. Yusuf (2011)
Apixaban in patients with atrial fibrillation.The New England journal of medicine, 364 9
J. Weitz (2009)
New oral anticoagulants in developmentThrombosis and Haemostasis, 103
Boehringer Ingelheim Pharma GmbH & Co. Pradaxa Ò (dabigatran etexilate) Prescribing information
W. Feinberg, J. Blackshear, A. Laupacis, R. Kronmal, R. Hart (1995)
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.Archives of internal medicine, 155 5
M. Glanz (2000)
The SharerAnnals of Internal Medicine, 132
J. Olesen, G. Lip, M. Hansen, P. Hansen, J. Tolstrup, J. Lindhardsen, C. Selmer, Ole Ahlehoff, A. Olsen, G. Gislason, C. Torp-Pedersen (2011)
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort studyThe BMJ, 342
S. Connolly, J. Pogue, R. Hart, M. Pfeffer, S. Hohnloser, S. Chrolavicius, S. Yusuf (2006)
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialThe Lancet, 367
J. Freeman, R. Zhu, D. Owens, A. Garber, D. Hutton, A. Go, Paul Wang, M. Turakhia (2011)
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial FibrillationAnnals of Internal Medicine, 154
(2011)
Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation
(2011)
Xarelto (rivaroxaban): summary of product characteristics [online]. Available from URL: http://www.xarelto.com/html/ downloads/Xarelto_Summary_of_Product_Characteristics_May2009.pdf [Accessed
I. Ogilvie, N. Newton, S. Welner, W. Cowell, G. Lip (2010)
Underuse of oral anticoagulants in atrial fibrillation: a systematic review.The American journal of medicine, 123 7
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 12
S. Connolly, J. Pogue, R. Hart, S. Hohnloser, M. Pfeffer, S. Chrolavicius, S. Yusuf (2009)
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.The New England journal of medicine, 360 20
L. Bereznicki, G. Peterson (2010)
New antithrombotics for atrial fibrillation.Cardiovascular therapeutics, 28 5
(2011)
Executive summary: heart disease and stroke statistics. 2011 update: a report from the American Heart AssociationCirculation, 123
A. Camm, P. Kirchhof, G. Lip, U. Schotten, I. Savelieva, S. Ernst, I. Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. Caterina, J. Sutter, A. Goette, B. Gorenek, M. Heldal, Stefan Hohloser, P. Kolh, J. Heuzey, P. Ponikowski, F. Rutten, A. Vahanian, A. Auricchio, Jeroen Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, Richard Hobbs, P. Kearney, T. McDonagh, B. Popescu, Željko Reiner, U. Sechtem, P. Sirnes, M. Tendera, P. Vardas, Petr Widimsky, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlöf, T. Folliguet, M. Glikson, M. Goethals, D. Gulba, S. Ho, R. Klautz, S. Kose, John Mcmurray, P. Filardi, P. Raatikainen, M. Salvador, M. Schalij, A. Shpektor, J. Sousa, J. Stȩpińska, H. Uuetoa, J. Zamorano, I. Zupan (2010)
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 12 10
L. Wann, A. Curtis, C. January, K. Ellenbogen, J. Lowe, N. Estes, R. Page, M. Ezekowitz, D. Slotwiner, W. Jackman, W. Stevenson, C. Tracy, V. Fuster, L. Rydén, D. Cannom, J. Heuzey, H. Crijns, S. Olsson, E. Prystowsky, J. Halperin, J. Tamargo, G. Kay, A. Jacobs, Jeffrey Anderson, N. Albert, J. Hochman, C. Buller, F. Kushner, M. Creager, E. Ohman, S. Ettinger, R. Guyton, L. Tarkington, C. Yancy (2011)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 57 2
M. Sobieraj-Teague, M. O’Donnell, J. Eikelboom (2009)
New anticoagulants for atrial fibrillation.Seminars in thrombosis and hemostasis, 35 5
A. Turpie (2007)
New oral anticoagulants in atrial fibrillation.European heart journal, 29 2
B. Gage, A. Waterman, W. Shannon, M. Boechler, M. Rich, M. Radford (2001)
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.JAMA, 285 22
(2011)
Pradaxa (dabigatran etexilate) Prescribing information [online]. Available from URL: http://www.pradax apro.com
G. Lip, R. Nieuwlaat, R. Pisters, D. Lane, H. Crijns (2010)
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.Chest, 137 2
R.D. Lopes, J.H. Alexander, S.M. Al-Khatib (2010)
Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation: (ARISTOTLE) trial — design and rationale [published erratum appears in Am Heart J 2010 Jun; 159(6): 1162]Am Heart J, 159
R. Investigators (2010)
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.American heart journal, 159 3
L.S. Wann, A.B. Curtis, K.A. Ellenbogen (2011)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol, 57
Samuel Wann, A. Curtis, K. Ellenbogen, N. Estes, M. Ezekowitz, W. Jackman, C. January, J. Lowe, R. Page, D. Slotwiner, W. Stevenson, C. Tracy, V. Fuster, L. Rydén, D. Cannom, H. Crijns, J. Halperin, G. Kay, J. Heuzey, S. Olsson, E. Prystowsky, J. Tamargo, L. Wann, A. Jacobs, Jeffrey Anderson, N. Albert, M. Creager, S. Ettinger, R. Guyton, J. Hochman, F. Kushner, E. Ohman, C. Yancy (2011)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Heart rhythm, 8 3
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is an independent risk factor of potentially catastrophic cardioembolic strokes. AF patients are categorized into high-, intermediate-, and low-risk for thromboembolic complications using the CHADS2 or CHA2DS2-VASc scoring system. Oral anticoagulation using warfarin has been the standard therapy for stroke prevention in intermediate- to high-risk AF patients. However, warfarin use has been limited by several factors such as narrow therapeutic windows, drug-drug and drug-food interactions, and hemorrhagic complications. Rigorous research evaluated dual antiplatelet therapy of clopidogrel and aspirin (acetylsalicylic acid) as a potential alternative to warfarin in the ACTIVE W trial. Dual antiplatelet therapy of clopidogrel and aspirin was found to be inferior to warfarin in preventing stroke and systemic embolism with increased bleeding risk. Other extensive research has led to the development of new antithrombotic agents. Recently, dabigatran etexilate 150 mg twice daily, a direct thrombin inhibitor, was approved by the US FDA for stroke prevention in patients with non-valvular AF after it was found to be superior to warfarin in preventing thromboembolic events and associated with less bleeding in the RE-LY trial. It was also cost effective when compared with warfarin. Dabigatran can be considered in high-risk AF patients who are unable or unwilling to comply with the frequent laboratory and clinic visits that are required when receiving treatment with warfarin. Factor Xa inhibitors are another class of new anticoagulants that have been developed. Oral rivaroxaban was non-inferior to warfarin in thromboprophylaxis and with similar bleeding in the ROCKET-AF trial (HR 0.88; p=0.117). Apixaban, another factor Xa inhibitor, was superior to aspirin in reducing stroke and systemic embolism in patients with AF in the AVERROES trial (HR 0.45; p<0.001). The results of the ARISTOTLE trial, which is evaluating apixaban against warfarin in ∼18 000 patients with AF, are expected to be available later this year. Edoxaban, another oral factor Xa inhibitor, is currently being evaluated against warfarin in the ENGAGE AF-TIMI 48 trial in ∼20 000 patients with AF. With these new developments, there is a necessity for the clinical practitioner to become familiar with these new and upcoming therapies and guidelines. This review provides an overview of the available data regarding the clinical usefulness of these agents.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.